search for




 

Original Article
A Multicenter Retrospective Analysis on the Treatment Pattern and Outcome in Relapsed/Refractory Childhood Acute Lymphoblastic Leukemia
Clin Pediatr Hematol Oncol 2017;24:101-6.
Published online October 31, 2017
© 2017 Korean Society of Pediatric Hematology-Oncology and Korean Society for Pediatric Neuro-Oncology

Keon Hee Yoo, M.D.1, Nak Gyun Chung, M.D.2, Bin Cho, M.D.2, Hyoung Jin Kang, M.D.3, Hee Young Shin, M.D.3, Ho Joon Im, M.D.4, Jong Jin Seo, M.D.4, Young Tak Lim, M.D.5, Chuhl Joo Lyu, M.D.6, Soon Ki Kim, M.D.7, In-Sang Jeon, M.D.8, Hoon Kook, M.D.9 and Hong Hoe Koo, M.D.1

1Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 2 Department of Pediatrics, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 3 Department of Pediatrics, Seoul National University Children’s Hospital, Cancer Research Institute, Seoul National University College of Medicine, 4Department of Pediatrics, Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine, Seoul, 5Department of Pediatrics, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, 6Department of Pediatrics, Severance Children’s Hospital, Yonsei University College of Medicine, Seoul, 7Department of Pediatrics, Inha University Hospital, Inha University College of Medicine, 8Department of Pediatrics, Gachon University Gil Medical Center, College of Medicine, Gachon University, Incheon, 9Department of Pediatrics, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Korea
Correspondence to: Hong Hoe Koo
Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea
Tel: +82-2-3410-3524 Fax: +82-2-3410-0043 E-mail: hhkoo@skku.edu
Received September 5, 2017; Revised September 13, 2017; Accepted September 25, 2017.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background: Although the overall survival of childhood acute lymphoblastic leukemia (ALL) approaches 85-90%, the prognosis of relapsed or refractory (R/R) ALL is grave. This study aimed to identify the treatment pattern, treatment response, and overall survival of these patients.Methods: We reviewed data of 64 patients with R/R ALL whose initial diagnosis of ALL had been made between 1 and 21 years of age. Patients who received clofarabine as part of an induction regimen were excluded. Relapsed patients were limited to those who relapsed after ≥2 prior induction regimens. Treatment patterns, response rates, and overall survival were analyzed.Results: Patients’ median age was 15.0 years (range, 6.0-25.0) at the diagnosis of R/R ALL. The most frequently used agents other than steroid were vincristine (54.0%), cytarabine (44.6%), and idarubicin (36.5%), while L-asparaginase was used in only one patient. The complete remission (CR) and overall response (OR) rates were 38.1 and 42.9%, respectively. Sixteen patients (25.4%) underwent allogeneic hematopoietic stem cell transplantation (HSCT). The 5-year overall survival was 6.7%. The survival of patients with HSCT was significantly higher compared with those without HSCT (35.2% vs 0%, P=0.0097). Among 14 patients who achieved CR or CR without platelet recovery (CRp) before HSCT, the 3-year survival was 46.9%. Conclusion: The survival of Korean patients with R/R childhood ALL was dismal despite a reasonable CR rate, whereas that of those who received HSCT after CR or CRp was excellent. More treatment options are needed to improve the overall outcome of R/R childhood ALL.
Keywords: Childhood, Acute lymphoblastic leukemia, Relapsed, Refractory
References
  1. Kim H. Recent advances in the treatment of pediatric acute leukemia. J Korean Med Assoc 2016;59:690-7.
    CrossRef
  2. Pui CH. Recent research advances in childhood acute lymphoblastic leukemia. J Formos Med Assoc 2010;109:777-87.
    CrossRef
  3. Kim SS, Cho B, Jeong DC, Kim HK. Ifosfamide and etoposide in relapsed refractory childhood acute lymphoblastic leukemia. Korean J Pediatr Hematol Oncol 1997;4:90-7.
  4. Bernstein ML, Abshire TC, Pollock BH, et al. Idarubicin and cytosine arabinoside reinduction therapy for children with multiple recurrent or refractory acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 1997;19:68-72.
    Pubmed CrossRef
  5. Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006;24:1917-23.
    Pubmed CrossRef
  6. Angiolillo AL, Yu AL, Reaman G, Ingle AM, Secola R, Adamson PC. A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report. Pediatr Blood Cancer 2009;53:978-83.
    Pubmed KoreaMed CrossRef
  7. Ko RH, Ji L, Barnette P, et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol 2010;28:648-54.
    Pubmed KoreaMed CrossRef
  8. Liu AP, Lee V, Li CK, Ha SY, Chiang AK. Refractory acute lymphoblastic leukemia in Chinese children: bridging to stem cell transplantation with clofarabine, cyclophosphamide and etoposide. Ann Hematol 2016;95:501-7.
    Pubmed CrossRef
  9. Yoon JH, Park JA, Kim EK, Kang HJ, Shin HY, Ahn HS. Improvement of induction remission rate by modifying the dose of idarubicin for relapsed childhood acute lymphoblastic leukemia. J Korean Med Sci 2009;24:281-8.
    Pubmed KoreaMed CrossRef
  10. Sakaguchi H, Watanabe N, Matsumoto K, et al. Comparison of donor sources in hematopoietic stem cell transplantation for childhood acute leukemia: A Nationwide Retrospective Study. Biol Blood Marrow Transplant 2016;22:2226-34.
    Pubmed CrossRef
  11. Atta EH, de Oliveira DC, Bouzas LF, Nucci M, Abdelhay E. Less graft-versus-host disease after rabbit antithymocyte globulin conditioning in unrelated bone marrow transplantation for leukemia and myelodysplasia: comparison with matched related bone marrow transplantation. PLoS One 2014;9:e107155.
    Pubmed KoreaMed CrossRef
  12. Inagaki J, Fukano R, Noguchi M, Kurauchi K, Tanioka S, Okamura J. Hematopoietic stem cell transplantation following unsuccessful salvage treatment for relapsed acute lymphoblastic leukemia in children. Pediatr Blood Cancer 2015;62: 674-9.
    Pubmed CrossRef
  13. von Stackelberg A, Locatelli F, Zugmaier G, et al. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol 2016;34:4381-9.
    Pubmed CrossRef
  14. Hijiya N, Barry E, Arceci RJ. Clofarabine in pediatric acute leukemia: current findings and issues. Pediatr Blood Cancer 2012;59:417-22.
    Pubmed CrossRef
  15. Hijiya N, Thomson B, Isakoff MS, et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood 2011;118:6043-9.
    Pubmed KoreaMed CrossRef
  16. Trioche P, Nelken B, Michel G, et al. French "real life" experience of clofarabine in children with refractory or relapsed acute lymphoblastic leukaemia. Exp Hematol Oncol 2012;1: 39.
    Pubmed KoreaMed CrossRef
  17. Lu A, Fang Y, Du X, et al. Efficacy, safety and pharmacokinetics of clofarabine in Chinese pediatric patients with refractory or relapsed acute lymphoblastic leukemia: a phase II, multi-center study. Blood Cancer J 2016;6:e400.
    Pubmed KoreaMed CrossRef
  18. Ceppi F, Duval M, Leclerc JM, et al. Improvement of the outcome of relapsed or refractory acute lymphoblastic leukemia in children using a risk-based treatment strategy. PLoS One 2016;11:e0160310.
    Pubmed KoreaMed CrossRef
  19. Einsiedel HG, von Stackelberg A, Hartmann R, et al. Long- term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87. J Clin Oncol 2005;23:7942-50.
    Pubmed CrossRef


April 2018, 25 (1)
Full Text PDF
Citation
Send to a friend
Twitter
Facebook

Cited By Articles
  • CrossRef (0)

Funding Information